Stock REVB REVELATION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Delayed Nasdaq
Other stock markets
 10:01:11 2024-07-03 am EDT 		5-day change 1st Jan Change
1.76 USD -1.68% Intraday chart for Revelation Biosciences, Inc. -11.56% -88.28%
Jun. 24 Revelation Biosciences Shares Jump on Positive Results for Investigational Drug Gemini MT
Jun. 24 Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity CI

Evolution of the average Target Price on Revelation Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ba1b4a9c295de.bOIpmdnTxMKUnhiYAdXtPfD-Op7TjnXZUkop8vQ135E.ArhA7IGJto38-SmoNKadYpWYafmYxTidDQUEts1Q694VqG7Y6IeD9NvQIA~e0b34add31ee6ad97d8a19c21a294662

Analyst Recommendations on Revelation Biosciences, Inc.

Roth MKM Adjusts Price Target on Revelation Biosciences to $15 From $5, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.79 USD
Average target price
18.7 USD
Spread / Average Target
+944.69%
High Price Target
25 USD
Spread / Highest target
+1,296.65%
Low Price Target
12.4 USD
Spread / Lowest Target
+592.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Revelation Biosciences, Inc.

Roth MKM

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. REVB Stock
  4. Consensus Revelation Biosciences, Inc.